CD274 and primary biliary cholangitis: The results of the JAVELIN Bladder 100 Phase III trial led to the approval of avelumab, a human anti-PD-L1 antibody, as a 1L maintenance therapy after PBC in aUC patients who did not experience disease progression, regardless of the PD-L1 status [7].